Pharma may face new fines under EU pharmacovigilance and paediatric regulations
This article was originally published in SRA
The European Commission is planning to impose new financial penalties on drug companies if they fail to fulfil certain obligations under the EU Paediatric Regulation and the new pharmacovigilance legislation1,2.
You may also be interested in...
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.
Drug companies will be able to “play around” with the new EU Clinical Trials Information System in a secure testing environment before it goes live in approximately 15 months.
The Canadian authorities have put in place an expedited pathway for authorizing new COVID-19 drugs and vaccines that offers a more agile approach to reviewing data than what was previously allowed.